Elixirgen Therapeutics is a biotechnology company focused on curing humanity’s ailments through stem cell biology. Founded in 2017 by Minoru S.H. Ko, M.D., Ph.D., a renowned specialist in stem cell biology, the company concentrates on regenerative and rejuvenative medicine, and deals with research in both basic science and in the application of the technologies it discovers and refines. Elixirgen Therapeutics is located in the Science + Technology Park at Johns Hopkins in Baltimore, an ideal research environment that allows Elixirgen Therapeutics’ scientists to conduct research at state-of-the-art facilities. Elixirgen Therapeutics inherits all the therapy-related assets, including intellectual property, from its parent company, Elixirgen, LLC, which has been in active operation since the beginning of 2012.